As Shanghai Observer reported on January 18th, in recent days, Medical School of Shanghai Jiaotong University granted an exclusive license to a Shanghai biotechnology company to exploit a target patent and its international patent families., i.e., Antibody heavy chain constant region sequence that enhances agonistic antibody activity. The total amount of the contract reached 300 million yuan. In 2019, the other targets of this patent have been exclusively licensed to a company in Suzhou, in a contract of 828 million yuan with the addition of sales commission. It is rare in China that one granted patent is divided to be sold to two companies to commercialize the patent achievements.
